![]() VIVUS VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. | ![]() UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | ![]() Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. | |
Founding Date | Founding Date 1991 | Founding Date 1928 | Founding Date 1935 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Campbell, US HQ | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more |
Employees | Employees 594% increase | Employees 9,052 | Employees 27,764 |
Valuation ($) | Valuation ($) 8.3 m | Valuation ($) 34.3 b | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) $69.8m (FY, 2019) | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) ₹277.1b (FY, 2026) |
Cost of goods | Cost of goods $15.7m (FY, 2019) | Cost of goods €1.4b (FY, 2025) | Cost of goods ₹95.5b (FY, 2026) |
Gross profit | Gross profit $54.1m (FY, 2019) | Gross profit €7.2b (FY, 2025) | Gross profit ₹195b (FY, 2026) |
Net income | Net income ($31.5m) (FY, 2019) | Net income €1.6b (FY, 2025) | Net income ₹38.7b (FY, 2026) |

UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View company